Advertisement
Advertisement
U.S. markets open in 7 hours 27 minutes
Advertisement
Advertisement
Advertisement
Advertisement

BioCardia, Inc. (BCDA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9799+0.1199 (+6.45%)
At close: 04:00PM EDT
2.0000 +0.02 (+1.02%)
After hours: 04:52PM EDT
Advertisement

BioCardia, Inc.

320 Soquel Way
Sunnyvale, CA 94085
United States
650 226 0120
https://www.biocardia.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees28

Key Executives

NameTitlePayExercisedYear Born
Dr. Peter A. Altman Ph.D.CEO, Pres & Director488.06kN/A1967
Mr. David McClungChief Financial Officer364.31kN/A1963
Mr. Edward M. GillisSr. VP of Devices267.79kN/A1962
Dr. Ian McNiece Ph.D.Chief Scientific OfficerN/AN/A1954
Dr. Sujith ShettyChief Medical Officer and VP of Clinical & RegulatoryN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Corporate Governance

BioCardia, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement